Patient characteristics
tumors
TUMORS
Between April 2018 and December 2020, 23 patients were screened. Two patients did not meet the inclusion criteria and 21 patients were finally enrolled and received at least one dose of GC1118 treatment. The median age was 57 years old (range: 37–71 years) and the male to female ratio was 10:11. Median Karnofsky performance status score was 70 (range: 70–90). The median number of GC1118 administrations was 7 (range: 4–22).According to revised 2021 WHO classification, all tumors were IDH1‐wild‐type GBMs. Methylation of the MGMT promoter was identified in eight patients (38.1% [8/21]). The number of prior treatments before GC1118 treatment were as follows: one prior treatment in 66.7% (14 patients); two prior treatments in 19.0% (four patients); and three or more prior treatments in 14.3% (three patients) (Table Baseline characteristics of study patients.Abbreviations: KPS, Karnofsky Performance Status scale; MGMT, OMedian values are presented.Prior treatment includes Stupp regimen, bevacizumab, low‐dose temozolomide, PCV, gamma‐knife radiosurgery, radiation therapy, and surgery other than primary surgery.For safety analysis, we included the patients who received at least one dose of GC1118 (